In 2019, the ST Gallen Advanced Prostate Cancer consensus conference (APCCC) recommended the use of mpMRI combined with PSMA-PET/CT, rather than WB-MRI, in patients with BCR after prostatectomy or radiotherapy (RT) [11]. The gene discussed is FOLH1; the disease is prostate cancer.